{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:31:30Z","timestamp":1772440290703,"version":"3.50.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/cnq.0b013e31820f6e88","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T22:40:53Z","timestamp":1381531253000},"page":"87-100","source":"Crossref","is-referenced-by-count":10,"title":["Multidrug-Resistant Gram-Negative Infections"],"prefix":"10.1097","volume":"34","author":[{"given":"Noreen H.","family":"Chan-Tompkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"8","key":"R1-2-20210126","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"R2-2-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":". Bad bugs, no drugs: no ESKAPE An update from the Infectious Diseases Society of America.","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R3-2-20210126","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1592\/phco.28.2.235","article-title":"The current state of multidrug-resistant gram-negative bacilli in North America.","volume":"28","author":"Nicasio","year":"2008","journal-title":"Pharmacother"},{"issue":"3","key":"R4-2-20210126","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum -lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices.","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"issue":"14","key":"R5-2-20210126","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/11315690-000000000-00000","article-title":"Multidrug-resistant gram-negative infections.","volume":"69","author":"Gimarellou","year":"2009","journal-title":"Drugs"},{"issue":"24","key":"R6-2-20210126","first-page":"750","article-title":"Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase--United States, 2010.","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"R7-2-20210126","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":". Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"R8-2-20210126","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/652152","article-title":"Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008.","volume":"31","author":"Kallen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"R9-2-20210126","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1592\/phco.21.6.583.34537","article-title":"Therapeutic challenges associated with extended-spectrum, -lactamase-producing Escherichia coli and Klebsiella pneumoniae.","volume":"21","author":"Wong-Beringer","year":"2001","journal-title":"Pharmacother"},{"key":"R10-2-20210126","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.diagmicrobio.2009.08.020","article-title":"Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).","volume":"65","author":"Rhomberg","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"suppl 2","key":"R14-2-20210126","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/504476","article-title":"The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.","volume":"43","author":"Paterson","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R15-2-20210126","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/522287","article-title":"A step closer to extreme drug resistance (XDR) in gram-negative bacilli.","volume":"45","author":"Paterson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"37","key":"R16-2-20210126","first-page":"1212","article-title":"Update: detection of a Verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae--United States, 2010.","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"R17-2-20210126","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1592\/phco.21.11.920.34529","article-title":"Extended-Spectrum -lactamases: epidemiology, detection, and treatment.","volume":"21","author":"Nathisuwan","year":"2001","journal-title":"Pharmacother"},{"key":"R18-2-20210126","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1086\/429239","article-title":"Risk factors for increasing multidrug resistance among extended-spectrum -lactamase-producing Escherichia coli and Klebsiella species.","volume":"40","author":"Hyle","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R19-2-20210126","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/jac\/dkm356","article-title":". Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study.","volume":"60","author":"Falagas","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"R20-2-20210126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3201\/eid1301.060716","article-title":". Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization.","volume":"13","author":"Sunenshine","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"R21-2-20210126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1086\/502018","article-title":"The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay.","volume":"23","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R22-2-20210126","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum -lactamase-producing Enterobacteriaceae.","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"R23-2-20210126","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":". Comparative review of the carbapenems.","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"R28-2-20210126","first-page":"1","article-title":"Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.","volume":"31","author":"Norrby","year":"1999","journal-title":"Scand J Infect Dis"},{"issue":"9","key":"R29-2-20210126","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00002018-200932090-00001","article-title":"Overview of seizure-inducing potential of doripenem.","volume":"32","author":"Zhanel","year":"2009","journal-title":"Drug Saf"},{"issue":"2","key":"R30-2-20210126","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1345\/aph.1E421","article-title":"Ertapenem-associated seizures in a peritoneal dialysis patient.","volume":"39","author":"Seto","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"8","key":"R31-2-20210126","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1592\/phco.27.8.1202","article-title":"Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.","volume":"27","author":"Lunde","year":"2007","journal-title":"Pharmacother"},{"key":"R32-2-20210126","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1345\/aph.1K079","article-title":"Interaction between valproate and meropenem: a retrospective study.","volume":"41","author":"Spriet","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R33-2-20210126","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/60.6.565","article-title":"Economic benefit of a meropenem dosage strategy based on pharmacodynamics concepts.","volume":"60","author":"Kuti","year":"2003","journal-title":"Am J Health-Syst Pharm"},{"key":"R36-2-20210126","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1345\/aph.18426","article-title":"Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.","volume":"33","author":"Evans","year":"1999","journal-title":"Ann Phamracother"},{"issue":"8","key":"R37-2-20210126","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/AAC.47.8.2659-2662.2003","article-title":"Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.","volume":"47","author":"Ouderkirk","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-2-20210126","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1345\/aph.1H543","article-title":"Tigecycline: a novel broad-spectrum antimicrobial.","volume":"41","author":"Slover","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R42-2-20210126","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigeycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R43-2-20210126","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R44-2-20210126","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/dkn311","article-title":"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.","volume":"62","author":"Kelesidis","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R45-2-20210126","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1345\/aph.1L171","article-title":"Tigecycline for the treatment of Acinetobacter infections: a case series.","volume":"42","author":"Gallagher","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R46-2-20210126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/526775","article-title":"Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.","volume":"46","author":"Anthony","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R47-2-20210126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R48-2-20210126","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/656289","article-title":"Tigecycline and bacteremia--the dangers of post hoc analysis of pooled data.","volume":"51","author":"Tarchini","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R50-2-20210126","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1345\/aph.1K346","article-title":". Parenteral polymyxin B in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.","volume":"42","author":"Pastewski","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R51-2-20210126","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R52-2-20210126","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":". Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections.","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"R53-2-20210126","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/00365540903490018","article-title":"Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant gram-negative bacterial infections.","volume":"42","author":"Huang","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"R54-2-20210126","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":". Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R55-2-20210126","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/599226","article-title":"Nephrotoxicity of colistin: new insight into an old antibiotic.","volume":"48","author":"Falagas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R56-2-20210126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1345\/aph.1E485","article-title":"Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection.","volume":"39","author":"Quinn","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R57-2-20210126","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1086\/650582","article-title":"Intravenous and inhalational colistin-induced respiratory failure.","volume":"50","author":"Wahby","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R60-2-20210126","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/jac\/dkh369","article-title":". Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections.","volume":"54","author":"Sobiszcyk","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R61-2-20210126","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/529198","article-title":"Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.","volume":"46","author":"Maragakis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R62-2-20210126","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1086\/652237","article-title":"The 10 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R63-2-20210126","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/655957","article-title":"Letter in response to the Infectious Diseases Society of Americas 10 20 initiative.","volume":"51","author":"Burgess","year":"2010","journal-title":"Clin Infect Dis"}],"container-title":["Critical Care Nursing Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CNQ.0b013e31820f6e88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:55:12Z","timestamp":1620950112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002727-201104000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cnq.0b013e31820f6e88","relation":{},"ISSN":["0887-9303"],"issn-type":[{"value":"0887-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}